Tag: pubmed

Polymers (Basel). 2023 Nov 16;15(22):4434. doi: 10.3390/polym15224434.

ABSTRACT

Polyurethane and polyurea-based adhesives are widely used in various applications, from automotive to electronics and medical applications. The adhesive performance depends strongly on its composition, and developing the formulation-structure-property relationship is crucial to making better products. Here, we investigate the dependence of the linear viscoelastic properties of polyurea nanocomposites, with an IPDI-based polyurea (PUa) matrix and exfoliated graphene nanoplatelet (xGnP) fillers, on the hard-segment weight fraction (HSWF) and the xGnP loading. We characterize the material using scanning electron microscopy (SEM) and dynamic mechanical analysis (DMA). It is found that changing the HSWF leads to a significant variation in the stiffness of the material, from about 10 MPa for 20% HSWF to about 100 MPa for 30% HSWF and about 250 MPa for the 40% HSWF polymer (as measured by the tensile storage modulus at room temperature). The effect of the xGNP loading was significantly more limited and was generally within experimental error, except for the 20% HSWF material, where the xGNP addition led to about an 80% increase in stiffness. To correctly interpret the DMA results, we developed a new physics-based rheological model for the description of the storage and loss moduli. The model is based on the fractional calculus approach and successfully describes the material rheology in a broad range of temperatures (-70 °C-+70 °C) and frequencies (0.1-100 s^-1), using only six physically meaningful fitting parameters for each material. The results provide guidance for the development of nanocomposite PUa-based materials.

PMID:38006160 | DOI:10.3390/polym15224434

Polymers (Basel). 2023 Nov 16;15(22):4417. doi: 10.3390/polym15224417.

ABSTRACT

This study aimed to extract and characterize the morphological, physicochemical, thermal, and rheological properties of the starches of native potatoes grown in the department of Puno. Among the varieties evaluated were sweet native potato varieties Imilla Negra (Solanum tuberosum spp. Andígena), Imilla Blanca (Solanum tuberosum spp. Andígena), Peruanita, Albina or Lomo (Solanum chaucha), and Sutamari, and the bitter potatoes Rucki or Luki (Solanum juzepczukii Buk), Locka (Solanum curtilobum), Piñaza (Solanum curtilobum), and Ocucuri (Sola-num curtilobum), acquired from the National Institute of Agrarian Innovation (INIA-Puno). The proximal composition, amylose content, and morphological, thermal, and rheological properties that SEM, DSC, and a rheometer determined, respectively, were evaluated, and the data obtained were statistically analyzed using a completely randomized design and then a comparison of means using Tukey’s LSD test. The results show a significant difference in the proximal composition (p ≤ 0.05) concerning moisture content, proteins, fat, ash, and carbohydrates. Thus, the amylose content was also determined, ranging from 23.60 ± 0.10 to 30.33 ± 0.15%. The size morphology of the granules is 13.09-47.73 µm; for the thermal and rheological properties of the different varieties of potato starch, it is shown that the gelatinization temperature is in a range of 57 to 62 °C and, for enthalpy, between 3 and 5 J/g.

PMID:38006141 | DOI:10.3390/polym15224417

Polymers (Basel). 2023 Nov 8;15(22):4350. doi: 10.3390/polym15224350.

ABSTRACT

In an interlayered carbon fiber-reinforced polycarbonate polymer (CFRPC) composite composed of three sized of CF plies, alternating between four PC sheets, designated [PC]₄[CF]₃, and a new process of activating CF cross-weave cloth plies directly on both sides with homogeneous low-energy electron beam irradiation (HLEBI) before lamination assembly and hot pressing at 6.0 MPa and 537 K for 8 min was produced. Experimental results show that a dose of 215 kGy of HLEBI raised the bending strength, σ_b, at each experimental accumulative probability, P_a, with the σ_b at a median P_a of 0.50, increasing by 25% over that of the untreated sample. Three-parameter Weibull analysis showed that when quality can be controlled, a dose of 215 kGy of HLEBI can raise the statistically lowest bending strength, σ_s, at P_a = 0 (94.3 Mpa), with a high correlation coefficient. This is because, although it had a higher bending strength than that in the other experimental conditions, the weakest sample of the 215 kGy data set had a much lower σ_b value than that of the others. Electron spin resonance (ESR) of the CF showed that naturally occurring dangling bonds in CF were increased at 215 kGy. Charge transfer to the PC occurs, apparently generating stronger bonds, which are possibly covalent, resulting in enhanced adhesion at the CF-PC interface.

PMID:38006075 | DOI:10.3390/polym15224350

Polymers (Basel). 2023 Nov 7;15(22):4344. doi: 10.3390/polym15224344.

ABSTRACT

The fabrication of PVDF-based nanofiber mats with enhanced β-phase using electrospinning and post processing was optimized using Taguchi design methodology. The parameters studied include the concentration of PVDF in the DMF (Dimethylformamide) solvent, applied voltage, flow rate, and drum speed. A reliable statistical model was obtained for the fabrication of bead-free PVDF nanofibers with a high fraction of β-phase (F(β)%). The validity of this model was verified through comprehensive regression analysis. The optimized electrospinning parameters were determined to be a 23 wt% PVDF solution, 20 kV voltage, a flow rate of 1 mL/h, and a drum speed of 1200 revolutions per minute.

PMID:38006068 | DOI:10.3390/polym15224344

Vaccines (Basel). 2023 Nov 16;11(11):1722. doi: 10.3390/vaccines11111722.

ABSTRACT

Significant progress has been made in vaccine development worldwide. This study examined the WHO African Region’s vaccine introduction trends from 2000 to 2022, excluding COVID-19 vaccines. We extracted data on vaccine introductions from the WHO/UNICEF joint reporting form for 17 vaccines. We examined the frequency and percentages of vaccine introductions from 2000 to 2022, as well as between two specific time periods (2000-2010 and 2011-2022). We analysed Gavi eligible and ineligible countries separately and used a Chi-squared test to determine if vaccine introductions differed significantly. Three vaccines have been introduced in all 47 countries within the region: hepatitis B (HepB), Haemophilus influenzae type b (Hib), and inactivated polio vaccine (IPV). Between 2011 and 2022, HepB, Hib, IPV, the second dose of measles-containing vaccine (MCV2), and pneumococcal conjugate vaccine (PCV) were the five most frequently introduced vaccines. Hepatitis A vaccine has only been introduced in Mauritius, while Japanese encephalitis vaccine has not been introduced in any African country. Between 2000-2010 and 2011-2022, a statistically significant rise in the number of vaccine introductions was noted (p < 0.001) with a significant positive association between Gavi eligibility and vaccine introductions (p < 0.001). Significant progress has been made in the introduction of new vaccines between 2000 and 2022 in the WHO African Region, with notable introductions between 2011 and 2022. Commitments from countries, and establishing the infrastructure required for effective implementation, remain crucial.

PMID:38006054 | DOI:10.3390/vaccines11111722

Vaccines (Basel). 2023 Nov 14;11(11):1715. doi: 10.3390/vaccines11111715.

ABSTRACT

Worldwide, conjugated pneumococcal vaccines (PCVs) have proven effective against invasive pneumococcal disease, but non-invasive pneumonia is a major cause of mortality in young children and serotypes vary geographically, affecting effectiveness. We analyze nationwide death certificate data between 2003-2017 to assess the impact of PCVs on pneumonia mortality among young children from Peru. We report descriptive statistics and perform timeseries analysis on annual mortality rates (AMRs) and monthly frequencies of pneumonia deaths. Children under 5 years of age accounted for 6.2% (n = 10,408) of all pneumonia deaths (N = 166,844), and 32.3% (n = 3363) were children between 1-4 years of age, of which 95.1% did not report pneumonia etiology. Comparing periods before and after PCV introduction in 2009, mean AMRs dropped 13.5% and 26.0% for children between 1-4 years of age (toddlers/preschoolers), and children under 1 year of age (infants), respectively. A moderate correlation (Spearman’s r = 0.546, p < 0.01) in the monthly frequency of pneumonia deaths was estimated between both age groups. Quadratic regression suggests a change in direction around 2005 (highest pneumonia mortality) for both age groups, but percentage change analysis identified an inflection point in 2013 for infants only, not for toddlers/preschoolers, suggesting that the impact of PCVs might be different for each age group.

PMID:38006047 | DOI:10.3390/vaccines11111715

Vaccines (Basel). 2023 Nov 11;11(11):1712. doi: 10.3390/vaccines11111712.

ABSTRACT

Seasonal influenza is a leading cause of death in the U.S., causing significant morbidity, mortality, and economic burden. Despite the proven efficacy of vaccinations, rates remain notably low, especially among Medicaid enrollees. Leveraging Medicaid claims data, this study characterizes influenza vaccination rates among Medicaid enrollees and aims to elucidate factors influencing vaccine uptake, providing insights that might also be applicable to other vaccine-preventable diseases, including COVID-19. This study used Medicaid claims data from nine U.S. states (2016-2021], encompassing three types of claims: fee-for-service, major Medicaid managed care plan, and combined. We included Medicaid enrollees who had an in-person healthcare encounter during an influenza season in this period, excluding those under 6 months of age, over 65 years, or having telehealth-only encounters. Vaccination was the primary outcome, with secondary outcomes involving in-person healthcare encounters. Chi-square tests, multivariable logistic regression, and Fisher’s exact test were utilized for statistical analysis. A total of 20,868,910 enrollees with at least one healthcare encounter in at least one influenza season were included in the study population between 2016 and 2021. Overall, 15% (N = 3,050,471) of enrollees received an influenza vaccine between 2016 and 2021. During peri-COVID periods, there was an increase in vaccination rates among enrollees compared to pre-COVID periods, from 14% to 16%. Children had the highest influenza vaccination rates among all age groups at 29%, whereas only 17% were of 5-17 years, and 10% were of the 18-64 years were vaccinated. We observed differences in the likelihood of receiving the influenza vaccine among enrollees based on their health conditions and medical encounters. In a study of Medicaid enrollees across nine states, 15% received an influenza vaccine from July 2016 to June 2021. Vaccination rates rose annually, peaking during peri-COVID seasons. The highest uptake was among children (6 months-4 years), and the lowest was in adults (18-64 years). Female gender, urban residency, and Medicaid-managed care affiliation positively influenced uptake. However, mental health and substance abuse disorders decreased the likelihood. This study, reliant on Medicaid claims data, underscores the need for outreach services.

PMID:38006044 | DOI:10.3390/vaccines11111712

Vaccines (Basel). 2023 Nov 10;11(11):1710. doi: 10.3390/vaccines11111710.

ABSTRACT

There is limited available data addressing whether inactivated COVID-19 vaccination before conception is associated with adverse neonatal outcomes. This cohort study included all singleton live births at our center from March 1 to June 30, 2022. According to whether a maternal inactivated COVID-19 vaccination had been administered within 3 months before conception or not, neonates were identified as being in the vaccinated or unvaccinated group. Vaccination information and clinical characteristics were extracted for analysis. Furthermore, neonatal outcomes were analyzed and compared between these two groups in the present study. The cohort included 856 eligible newborns, of whom 369 were exposed to maternal vaccination before conception and 487 were unexposed newborns. No differences were observed in rates of preterm birth, newborns being small for gestational age, or neonatal intensive care unit admission between exposed and unexposed newborns. Furthermore, even after adjusting for social-economic status and maternal characteristics, there remained no significant differences in these neonatal outcomes. Our study revealed no statistically significant differences between newborns born to women who received inactivated vaccines prior to conception compared with those who did not receive any vaccinations. In addition, our study also highlights the importance of considering COVID-19 vaccination before conception.

PMID:38006042 | DOI:10.3390/vaccines11111710

Vaccines (Basel). 2023 Nov 8;11(11):1702. doi: 10.3390/vaccines11111702.

ABSTRACT

Although the anti-COVID-19 vaccination has proved to be an effective preventive tool, “breakthrough infections” have been documented in patients with complete primary vaccination courses. Most of the SARS-CoV-2 neutralizing antibodies produced after SARS-CoV-2 infection target the spike protein receptor-binding domain which has an important role in facilitating viral entry and the infection of the host cells. SARS-CoV-2 has demonstrated the ability to evolve by accumulating mutations in the spike protein to escape the humoral response of a host. The aim of this study was to compare the titers of neutralizing antibodies (NtAbs) against the variants of SARS-CoV-2 by analyzing the sera of recovered and vaccinated healthcare workers (HCWs). A total of 293 HCWs were enrolled and divided into three cohorts as follows: 91 who had recovered from SARS-CoV-2 infection (nVP); 102 that were vaccinated and became positive after the primary cycle (VP); and 100 that were vaccinated with complete primary cycles and concluded the follow-up period without becoming positive (VN). Higher neutralization titers were observed in the vaccinated subjects’ arms compared to the nVP subjects’ arms. Differences in neutralization titers between arms for single variants were statistically highly significant (p < 0.001), except for the differences between titers against the Alpha variant in the nVP and in VP groups, which were also statistically significant (p < 0.05). Within the nVP group, the number of subjects with an absence of neutralizing antibodies was high. The presence of higher titers in patients with a complete primary cycle compared to patients who had recovered from infection suggested the better efficacy of artificial immunization compared to natural immunization, and this further encourages the promotion of vaccination even in subjects with previous infections.

PMID:38006034 | DOI:10.3390/vaccines11111702

Vaccines (Basel). 2023 Nov 7;11(11):1696. doi: 10.3390/vaccines11111696.

ABSTRACT

Vaccination is the most cost-effective method of preventing COVID-19; however, data on its effect on patients with multimorbidity is limited. The aim was to evaluate the effect of vaccination against new coronavirus infection (NCI) in patients with multimorbid pathology in hospital treatment on the outcome of COVID-19 disease. An analysis was carried out of 1832 records of patients in one of the COVID-19 hospitals in Moscow for 2020-2022. Statistical analysis was carried out using the StatTech v. 3.1.3 software, and the binary logistic regression (BLR) method was used to obtain prognostic models. The median age of patients was 69 years, and 76% of them had received two vaccine doses. To assess the outcome of the disease, two prognostic models were obtained depending on the presence of a multimorbidity in patients: cardiovascular pathology and/or atherosclerosis and/or type 2 diabetes mellitus (Model 1) or atherosclerosis and/or type 2 diabetes mellitus and/or encephalopathy (Model 2), against the background of the presence or absence of vaccination against NCI. When assessing the outcome of NCI in Model 1, the odds of death decreased by 3.228 times with two doses of Sputnik V in patients with multimorbidity. According to Model 2, for patients with multimorbidity, the chances of death decreased by 3.281 times with two doses of Sputnik V. The presence of two doses of Sputnik V increased the likelihood of recovery in patients with multimorbidity by more than three times.

PMID:38006028 | DOI:10.3390/vaccines11111696